NCT07823049招募中3 期
A Randomized, Double-blind, Multicenter Phase III Clinical Study Comparing XNW28012 Versus Placebo in Combination With Best Supportive Care in Patients With Metastatic Pancreatic Cancer Who Have Received Prior Systemic Therapy
Evopoint Biosciences Inc.48 个研究点 分布在 1 个国家目标入组 226 人开始时间: 2025年7月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 226
- 试验地点
- 48
- 主要终点
- The time from the date of subject enrollment to the date of death from any cause
研究概览
简要总结
This study was a randomized, double-blind, multicenter phase III clinical study.
A total of 226 patients with metastatic pancreatic ductal carcinoma who had failed or were intolerant to two previous standard therapies were planned.Subjects will be randomized in a 2:1 ratio to either the experimental group or the control group:Experimental Group: XNW28012 for Injection (2.4 mg/kg, administered once every 3 weeks);Control group: XNW28012 mimetic for Injection (administered once every 3 weeks).Both experimental and control subjects will receive optimal supportive care, including but not limited to nutritional support, adjustment of electrolyte balance, and cancer pain support treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic pancreatic ductal adenocarcinoma (PDAC), including adenosquamous carcinoma, confirmed histologically or cytologically.
- •Disease progression or toxicity intolerance after receiving two previous standard therapies (gemcitabine and fluorouracil-based chemotherapy).
- •Men and women were 18 years of age or older at the time of informed consent. At least one measurable lesion met RECIST 1.1 criteria. The region should have received no previous local treatment, such as radiotherapy, or there should be evidence of definite progression after the completion of local treatment, such as radiotherapy.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Subjects had to have adequate levels of organ function within 7 days before randomization.
- •Female subjects of childbearing potential had to undergo a urine pregnancy or serum pregnancy test with a negative result within 7 days before randomization. If the urine pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test must be performed.
- •Use of a medically approved, highly effective contraceptive method during the study and for 6 months after the last administration of study medication; Male subjects whose partner is a female of reproductive age should be surgically sterilized or agree to use an effective method of contraception during the study and for 6 months after the last study dose. In addition, male participants had to agree not to donate sperm during the study and for 6 months after the last study dose.
- •I have signed the informed consent form and am willing and able to follow the study procedures required by the protocol.
排除标准
- •Patients with prior severe infusion reactions to macromolecular drugs such as antibody-drug conjugates (ADCs) or monoclonal antibodies, or allergic reactions to any component of XNW28012; patients with prior exposure to ADCs with a topoisomerase I inhibitor payload or TF-targeted anti-tumor agents.
- •Inadequate washout period from previous antineoplastic therapy before the first study drug, defined as follows:Chemotherapy or small molecule targeted therapy <2 weeks or 5 half-lives, whichever is shorter;Macromolecule monoclonal antibody treatment <3 weeks;Hormone therapy <3 weeks;Anti-tumor Chinese patent Medicine (with clear indications in the package insert) <2 weeks;Brain radiotherapy <2 weeks, palliative radiotherapy <2 weeks, and radical radiotherapy <4 weeks.
- •Any active malignancy, with the exception of the specific cancers studied in this trial and any cured localized neoplasm, e.g., eradicated noninvasive basal cell or squamous cell carcinoma, noninvasive superficial bladder cancer, carcinoma in situ of the cervix or breast, etc.
- •Receive live vaccine within 4 weeks before randomization. Note: Seasonal influenza vaccine is generally inactivated vaccine and can be used. However, intranasal influenza vaccines are not permitted if they are live attenuated.
- •Use of granulocyte colony-stimulating factor (G-CSF) or granulocyte/macrophage colony-stimulating factor within 1 week before randomization or pegylated G-CSF within 2 weeks before randomization. He had received a blood transfusion within 2 weeks before randomization. Erythropoietin (EPO) or IL-11 was administered within 1 week before randomization.
- •Hypoalbuminemia that was difficult to correct within 7 days before randomization.
- •Within 3 days before randomization, an ECOG score increase of ≥1 point from the ICF signing score or a weight loss of ≥10%.
- •Subjects who have not recovered to CTCAE grade ≤1 or stable toxicity from prior anticancer therapy, except for adverse events that are not considered to be a possible safety risk (e.g., alopecia or pigmentation).
- •Previous history of cerebral arteriovenous malformation, cerebral aneurysm, or stroke (including transient ischemic attack within 1 month before screening, except old or asymptomatic cerebral infarction).
- •Presence of any of the following hematologic risk factors:Known coagulation defects resulting in an increased risk of bleeding;Diffuse alveolar hemorrhage due to vasculitis;Known bleeding-prone constitution;Persistent heavy bleeding;Trauma that increases the risk of life-threatening bleeding;History of severe cranial trauma or intracranial surgery within 8 weeks prior to the start of the trial.
- •Subjects who are unwilling or unable to provide tumor tissue samples that meet the requirements for tissue factor (TF) expression detection.
- •Presence of clinically significant cardiovascular/cerebrovascular disease:History of unstable angina pectoris;Myocardial infarction within 6 months before screening;Angioplasty or cardiac stenting within 6 months before screening;History of New York Heart Association (NYHA) class 3-4 congestive heart failure;Abnormal QTc interval at baseline (QTcF > 480 ms);Occurrence of grade ≥ 2 ventricular arrhythmias and/or grade III atrioventricular block requiring clinical management within 6 months prior to screening;Poorly controlled hypertension: systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg while using standard antihypertensive therapy;Presence of cardiac disease/history resulting in a left ventricular ejection fraction (LVEF) < 50%.
- •Subjects with central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Subjects with previous cicatricial conjunctivitis and active eye diseases during the screening period; Subjects with glaucoma of CTCAE grade ≥
- •A history of toxic epidermal necrolysis (TEN) or Steven Johnson syndrome.
- •Major surgery, except minimally invasive procedures (e.g., peripherally inserted central catheter), was performed within 4 weeks before randomization.
- •Subjects with active hepatitis B (HBsAg and/or HbcAb positive but HBV DNA<2000 IU/mL), active hepatitis C (HCV antibody positive but HCV RNA negative), and HIV antibody positive;
- •Use of systemic antibacterial, antifungal, or antiviral agents within 14 days prior to randomization to allow antiviral therapy for subjects with viral hepatitis.
- •The presence of immunodeficiency conditions requiring treatment or systemic use of corticosteroids (≥10 mg/ day of prednisone or another corticosteroid at a pharmacologic physiological dose) or other immunosuppressive drugs within 7 days before randomization.
- •Receipt of a strong CYP3A4 inhibitor or inducer or a strong CYP2D6 inhibitor within 2 weeks or five half-lives, whichever was shorter, before the first study drug.
- •Present with the following health conditions, including but not limited to:Clinically relevant bilateral hydronephrosis that is not relieved by ureteral or percutaneous drainage;Complete biliary obstruction;the presence of acute or chronic inflammatory skin diseases;the presence of inflammatory lung disease, including but not limited to moderate/severe asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease;High risk of rupture and bleeding or GI/respiratory fistula due to tumor invasion of surrounding vital structures such as large blood vessels, trachea, etc.
- •Presence of clinical symptoms or signs of gastrointestinal obstruction within 4 weeks before randomization; A history of chronic diarrhoea, gastrointestinal perforation, fistula or bleeding; Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
- •Presence of uncontrolled serous effusion requiring frequent drainage or medical intervention (e.g., pleural effusion, peritoneal effusion, pericardial effusion, etc.) within 14 days before randomization, requiring additional intervention within 2 weeks after intervention, excluding exfoliative cytology of exudate.
- •Pregnant, lactating women, or subjects who planned to become pregnant during the study period.
- •There are diseases that the investigator considers to be detrimental to the study treatment or interfere with the judgment of drug toxicity/adverse events; Or the presence of alcohol or drug abuse; Or subjects who, as judged by the investigator, were not compliant during the study.
研究组 & 干预措施
XNW28012 for injection
Active Comparator
XNW28012 for injection (2.4 mg/kg, administered once every 3 weeks)
干预措施: XNW28012 for injection (Drug)
XNW28012 mimetic for injection
Placebo Comparator
XNW28012 Mimetic for Injection (administered once every 3 weeks)
干预措施: XNW28012 Mimetic for Injection (Drug)
结局指标
主要结局
The time from the date of subject enrollment to the date of death from any cause
时间窗: through study completion, an average of 2 year
次要结局
- Progression free survival (PFS)(through study completion, an average of 2 year)
- Objective response rate (ORR)(through study completion, an average of 2 year)
- Disease control rate (DCR)(through study completion, an average of 2 year)
- Duration of response (DOR)(through study completion, an average of 2 year)
- Time to Response (TTR)(through study completion, an average of 2 year)
- The incidence and severity of adverse events (AEs) and serious adverse events (SAEs).(through study completion, an average of 2 year)
- Maximum (peak) observed concentration (Cmax) of total antibody of XNW28012 TAb(through study completion, an average of 2 year)
- Anti-drug antibody (ADA)(through study completion, an average of 2 year)
- Tissue factor expression(through study completion, an average of 2 year)
- Maximum (peak) observed concentration (Cmax) of XNW28012(through study completion, an average of 2 year)
- Maximum (peak) observed concentration (Cmax) of YL0010014(through study completion, an average of 2 year)
研究者
研究点 (48)
Loading locations...
相似试验
尚未招募
3 期
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular LymphomaNCT07355283ImmuneOnco Biopharmaceuticals (Shanghai) Inc.198
尚未招募
3 期
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerHepatocellular CarcinomaNCT07823348Shanghai Junshi Bioscience Co., Ltd.560
尚未招募
2 期
Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT07408609Jiangsu Cancer Institute & Hospital114
尚未招募
不适用
A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia (AIHA)NCT07518277Chen Miao216
招募中
3 期
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus ComplexVentilator Associated Bacterial Pneumonia (VABP)Colistin Resistanrt ABCAcinetobacter Baumannii-calcoaceticus ComplexNCT07326540BioVersys SAS248